Funder
TEC
Japan Agency for Medical Research and Development
AMED
Subject
Cell Biology,Molecular Biology,Biochemistry,Biophysics
Reference29 articles.
1. Discovery of TAK-875: a potent, selective, and orally bioavailable GPR40 agonist;Negoro;ACS Med. Chem. Lett.,2010
2. Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial;Kaku;Diabetes Obes. Metabol.,2015
3. Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study;Kaku;Diabetes Obes. Metabol.,2016
4. Bile acid transporters and regulatory nuclear receptors in the liver and beyond;Halilbasic;J. Hepatol.,2013
5. Fasiglifam (TAK-875) alters bile acid homeostasis in rats and dogs: a potential cause of drug induced liver injury;Wolenski;Toxicol. Sci.,2017
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献